Osteoprotegerin (OPG) inhibits vascular calcification in vitro, and OPG 2/2 mice develop vascular calcification. Insulinlike growth factor-1 (IGF1) signalling has been implicated in vascular smooth muscle cell (VSMC) survival; however, the role of IGF1-receptor (IGF1R) expression in calcification is unclear. We sought to determine whether the protective effects of OPG in vascular calcification were mediated by IGF1R.
Introduction
Although Virchow first described calcium deposition in soft tissue over 100 years ago, its clinical significance and association with cardiovascular events is only just being realized (reviewed in ref. 1) . 1 Vascular calcification often occurs with aging, atherosclerosis, diabetes, and chronic kidney disease and involves multiple proteins, cytokines, and transcription factors known to regulate bone homeostasis and mineralization. 2 The RANKL/RANK/OPG cytokine system finely controls bone turnover, with RANKL activating downstream signalling pathways required for osteoclast development and function, whereas osteoprotegerin (OPG) acts as a soluble decoy receptor for RANKL. Imbalances in the RANKL/OPG ratio or RANKL/RANK/OPG signalling trigger pathologies that include excessive bone loss or formation, or disordered bone remodelling (reviewed in Collin-Osdoby 3 ).
Vascular calcification coincides with bone loss or osteoporosis, and factors such as OPG, known to inhibit osteoclastic bone resorption/ bone loss, may also prevent arterial calcification. This is particularly evident in OPG 2/2 mice, since these animals exhibit osteoporosis and develop vascular calcification of large arteries. 4 This is associated with vascular smooth muscle cell (VSMC) phenotypic transformation to osteogenic-like cells 2, 5 and expression of bone matrix proteins.
Thus, OPG may be a key molecule controlling this phenotype. † Equal contribution.
Interestingly, expression of OPG as a transgene in OPG 2/2 mice leads to normal vessel architecture, although vascular mineralization once established cannot be reversed by exogenous administration of OPG. 6 Administration of OPG also limits the calcified area within atherosclerotic lesions, but not lesion size per se, 7 and, in vitro, OPG demonstrates direct proliferative 8 and survival 9 effects on VSMCs.
In this study, we show that OPG can also inhibit calcium-induced vascular calcification of VSMCs in vitro. Despite this knowledge, the precise pathomechanism(s) by which OPG inhibits vascular calcification in vivo remains unclear.
Insulin-like growth factor-1 (IGF1) receptor (IGF1R) signals are vital for proliferation, survival, and migration of many cells including VSMCs. 10, 11 Both IGF1 and IGF1R are expressed in tissues of vascular pathology. 12, 13 IGF1 is also expressed in bone and acts to promote bone formation. 14 Recently, IGF1 signalling was implicated in the regulation, proliferation, and osteoblastic differentiation of calcifying vascular cells. 15 Although this study demonstrated the involvement of the extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways, direct IGF1R expression and activity in regulating VSMC calcification 15 was not examined, and the role of the IGF1R expression in vascular calcification is presently unclear. Here, we show for the first time that calcium via OPG regulates IGF1R expression in VSMCs, and protects against calcium-inducible calcification by enhancing survival of VSMCs. We conclude that calcium-inducible IGF1R expression is biphasic and regulated via a feedback mechanism; high calcium leads to inhibition of IGF1R expression, whereas moderate calcium induces IGF1R expression via OPG, which can inhibit vascular calcification in vitro.
Methods

Cell culture
Unless specified, all experiments involving human VSMCs were purchased from ATCC. In other experiments, VSMCs were isolated from aortas of patients undergoing cardiac transplantation under informed consent.
Approval of the Huntington Ethics Committee was obtained in all cases. Human cells were cultured in DMEM (Sigma-Aldrich) or Waymouth's medium (Invitrogen), with 20% foetal calf serum (FCS) and not used beyond passage 10. Pup rat WKY12-22 VSMCs 16 were cultured in Waymouth's medium. Wild-type IGF1R or kinase-inactive (IGF1R-YF) pBMN IRES-puro expressing rat VSMCs were described previously. 10 Where calcium was added exogenously, cells were serum-starved in M199 (Sigma-Aldrich) containing 1.36 mM calcium. Media were supplemented with 10 U/mL penicillin, 10 mg/mL streptomycin, and 1 mM L-glutamine. Cells were kept at 378C in a humidified atmosphere of 5% CO 2 .
Plasmid constructs
2476/+640 and 2188/+640 were provided by Haim Werner (Tel-Aviv University, Israel). pEBG-NLS and pEBG-Sp1 were obtained from Gerald Thiel (Institute for Genetics, University of Cologne). pRL-TK was purchased from Promega.
Calcification assay
Rat VSMCs cells were serum-starved in 1% FCS M199 at 70% confluence. Calcium was added every 2 -3 days with replenishment of fresh medium. Cells were harvested at 21 days. For human VSMCs, serum-starved cells (24 h) were treated with a total of 2.7 mM calcium together with OPG (R&D Systems). Human VSMCs were harvested 7 days later for quantification of calcification using a simple alizarin red-based assay. 17 
Transfection and luciferase assays
WKY12-22 VSMCs at 50-60% confluency in 6-well plates were serumstarved for 24 h, prior to transfection of indicated constructs using FuGENE6 (Roche) for a further 24 h. For luciferase assays, 1 mg/well 2476/+640 and 2188/+640 together with 100 ng/well of pRL-TK (Promega) were transiently transfected. Luciferase activity was quantified as described previously. 10 
siRNA studies
VSMCs were transfected with OPG siRNA (Qiagen), Sp1 siRNA (Thermo Scientific Dharmacon), and AllStar control siRNA (Qiagen) using lipofectamine (Invitrogen) or FuGENE6 for 4 -6 h in M199 containing 3.3 mM calcium or 1 ng/mL OPG. Cells were incubated for a further 20 h in M199 supplemented with calcium or OPG. RNA was isolated using the RNeasy Figure 1 Calcium-induced calcification is blocked by OPG and in VSMCs expressing wild-type IGF1R. (A) Human VSMCs were treated with OPG and calcium (2.7 mM). Cells were serum-starved for 24 h prior to treatment for 7 days. Cells were fixed and stained with alizarin red as described in the methods. (B) Rat VSMCs expressing wild-type (IGF1R-WT) and dominant-negative-IGF1R (IGF1R-DN) were treated with calcium in 1% FCS for 21 days. Cells were fixed and stained with alizarin red as described in the methods. **P , 0.01; ***P , 0.001 (n ¼ 3).
Kit (Qiagen). cDNA was reverse transcribed using Omniscript RT-kit (Qiagen). PCR for OPG and IGF1R was performed using a 7500 Fast-Real-Time-PCR System (Applied Biosystems). Cyclophilin was used as a control. Primer sequences were as follows: OPG sense
′ -CCCTCCACCCATTTGCT-3 ′ , and cyclophilin anti-sense 5 ′ -CAATCCAGCTATGGGA-3 ′ . For total protein, cell lysates were harvested in 1× SDS sample buffer for western blotting.
Western blotting
Total protein was extracted as previously described 13 or by scraping in 1× SDS sample buffer. IGF1Rb was detected using rabbit polyclonal antibody (1:2500; Santa Cruz); OPG was detected using mouse monoclonal antibody (1:500; R&D Systems); nuclear factor-kappa B (NFkB) was detected using a mouse monoclonal antibody (1:500, Santa Cruz); Bcl2 (B cell lymphoma 2) was detected using a rabbit polyclonal antibody (1:500, Santa Cruz); b-actin was detected using mouse monoclonal antibody (1:10 000; Sigma-Aldrich). Polyclonal swine anti-rabbit (1:2500) or goat anti-mouse (1:2500) HRP-conjugated secondary antibodies were used (Dako). Proteins were visualized by chemiluminescence (Perkin Elmer).
Real-time quantitative PCR for IGF1R and OPG
Total RNA was isolated as described previously. 13 Expression of IGF1R, OPG, and b-actin were analysed using a Rotor-Gene 3000 (Corbett Research) and Taqman expression assay systems (Applied Biosystems).
Values were normalized to b-actin.
Proliferation assays and cell death detection ELISA
Plus WKY12-22 VSMCs were seeded into 96-well plates (6000 cells/well). Cells were serum arrested for 24 h. Calcium was added for a further 24 h in M199. Cells were harvested with trypsin/EDTA and total cell counts measured by the Coulter Counter (Beckman Coulter). To assess apoptosis, the Cell Death Detection ELISA Plus (Roche) system was used. 18 Briefly, serum-starved VSMCs were treated with 0.2 ng/mL camptothecin (CAM) shown to induce apoptosis in WKY12-22.
18
Calcium was added to the medium at the same time as CAM treatment and left for 24 h prior to determination of histone release/DNA fragmentation by ELISA. Absorbance readings were normalized to total cell numbers.
Immunohistochemistry
Tissue sections were obtained from patients undergoing endarterectomy, and also from aortas obtained from transplant donors with appropriate (D) Human VSMCs were serum-starved and treated with OPG for 24 h. IGF1R protein levels were assessed by western blotting. b-actin demonstrated unbiased loading. The intensity of IGF1R expression relative to b-actin was determined by densitometry (n ¼ 4). (E) Transient transfection in pup rat VSMCs using 2476/+640 and pRL-TK. The dual luciferase assay was used to determine luciferase activity, normalized to the renilla (n ¼ 3). SF, serum free; *P , 0.05.
IGF1R inhibits VSMC calcification via OPG ethical approval, and conforms with the principles outlined in the Declaration of Helsinki. Tissues were processed as previously described. 19 Sections were stained with IGF1R (Santa Cruz; 1:100), OPG (R&D Systems; 1:50), smooth muscle-a actin (SMA, Sigma; 1:100), and von Kossa for calcification. IgG controls were negative.
Statistics
Differences between groups were assessed with Student's t-test and/or one-way ANOVA. All data are expressed as mean + SEM. A value of P , 0.05 was considered to indicate statistical significance.
Results
Calcium-induced calcification is blocked by OPG and in VSMCs expressing wild-type IGF1R
OPG 2/2 mice develop medial calcification of renal and aortic arteries, 4 suggesting that OPG plays a protective role in vascular calcification. 3 We therefore assessed inhibition of calcium-induced calcification in VSMCs using recombinant OPG and an in vitro alizarin red-based assay. 17 Consistent with a protective role of OPG in vascular calcification, we observed reduced calcification in VSMCs exposed for 7 days to 2.7 mM calcium and OPG at 0.1-1.0 ng/mL ( Figure 1A) .
To test the role of IGF1R in vascular calcification, VSMCs were transfected with dominant-negative IGF1R (DN-IGF1R). This induced a profound increase in calcium-induced calcification at 3.1 and 3.3 mM calcium ( Figure 1B) . In contrast, no calcification was observed in the wild-type IGF1R-expressing VSMCs ( Figure 1B) . These findings suggest that IGF1R expression and activity is essential for inhibiting calcium-induced vascular calcification in VSMCs.
OPG regulates IGF1R expression in VSMCs
We next tested whether OPG controls IGF1R expression in human VSMCs. OPG siRNA decreased serum-inducible IGF1R mRNA and protein expression (Figure 2A and B) and as expected inhibited OPG (Figure 2A and B) . To determine whether OPG could directly regulate IGF1R, serum-starved human VSMCs were treated with OPG at 0.1, 1.0, and 10 ng/mL for 24 h and IGF1R expression was analysed. Figure 2C and D demonstrates increased IGF1R mRNA and protein following OPG treatment. To determine whether OPG may influence the transcription of IGF1R, we performed transient transfections in VSMCs using 2476/+640, a luciferase reporter vector, driven by 1000 bp of the rat IGF1R promoter. 20 OPG increased IGF1R promoter activity ( Figure 2E) . Interestingly, OPG-inducible IGF1R expression was biphasic with a decline when the cells were exposed to 10 ng/mL of OPG ( Figure 2C -E) . Taken together, these studies demonstrate for the first time that OPG regulates IGF1R expression in VSMCs.
Calcium regulates IGF1R expression in VSMC
IGF1-IGF1R can modulate calcium-dependent signalling pathways. 21 Whether calcium can modulate IGF1R is unknown. To validate a role for calcium in regulating IGF1R expression, we treated pup rat VSMCs with the calcium chelator, ethylene glycol tetraacetic acid (EGTA), prior to serum induction. EGTA inhibited serum-inducible IGF1R protein expression in a dose-dependent manner ( Figure 3A ) and, indeed, calcium induced IGF1R protein expression in rat ( Figure 3B ) and human VSMCs ( Figure 3C ). Calcium's induction of IGF1R protein was dose dependent, with maximum expression at 3.3 mM. Concentrations of calcium .5.4 mM inhibited IGF1R levels in human VSMCs ( Figure 3C) . Furthermore, calcium induction of IGF1R was time dependent with optimum levels observed after 12 h ( Figure 3D ). Calcium can also regulate OPG in osteoblasts. 22 Similarly, in VSMCs calcium time-dependently increased OPG expression, with maximum induction at 48 h, suggesting that chronic exposure to calcium leads to substantial increases in OPG protein ( Figure 3D ). We next hypothesized that calcium-induced IGF1R expression could be modulated by OPG. Consistent with this, OPG siRNA inhibited calcium-inducible IGF1R and OPG mRNA in human VSMCs ( Figure 3E ). OPG siRNA also blocked OPG and IGF1R protein following calcium treatment ( Figure 3F ). These studies suggest that calcium can regulate IGF1R via OPG in VSMCs.
OPG and calcium regulate IGF1R expression via Sp1
Calcium dose dependently increased IGF1R transcription ( Figure 4A ).
To identify transcription factors that may play a role in calcium-and OPG-induced IGF1R transcription ( Figure 2E) , we examined the effect of calcium (3.3 mM) and OPG (1 ng/mL) on deletions of the IGF1R promoter. Although the full-length IGF1R promoter (2476/+640) was responsive to OPG and calcium, in contrast, 2188/+640 failed to respond ( Figure 4B ). This suggested that calcium-and OPG-inducible IGF1R transcription occurred between 
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2476 and 2188. Multiple specificity protein-1 (Sp1) elements lie within this region. 23 We next used a DN-mutant Sp1 (pEBG-Sp1) expression vector, which upon overexpression competes with endogenous Sp1 by binding DNA, but is unable to transactivate. 24 OPG-and calcium-inducible IGF1R protein expression was reduced following pEBG-Sp1 overexpression compared with its back-bone control in pup rat VSMCs (pEBG-NLS; Figure 4C and D). This finding was also validated by Sp1 siRNA studies in human VSMCs ( Figure 4E) . Thus, these results implicate Sp1 in calcium-and OPG-inducible IGF1R gene expression.
Calcium inhibits CAM-induced apoptosis and up-regulates anti-apoptotic genes
IGF1-IGF1R signalling promotes proliferation, migration, survival, and transformation. 11 Given that calcium regulates IGF1R expression via OPG, we next investigated the effect of calcium on proliferation and apoptosis of VSMCs. Calcium did not alter VSMC counts over 48 h ( Figure 5A ). CAM, a DNA-topoisomerase I inhibitor, induced apoptosis in these cells approximately two-fold ( Figure 5B, left) , and calcium at 3.1 -3.3 mM concentrations significantly inhibited CAM-induced apoptosis ( Figure 5B, right) . Interestingly, calcium treatment increased levels of the anti-apoptotic protein Bcl2 and NFkB (p65), a transcription factor important in activation of survival genes including the IGF1R 13,25 ( Figure 5C ). These findings suggest that moderate levels of calcium do not affect VSMCs proliferation, but may mediate survival signals.
OPG and IGF1R are expressed in calcified tissue
We next examined whether a link between OPG and IGF1R signals and expression exists in vivo and stained six atherosclerotic lesions with varying degrees of calcification. IGF1R and OPG co-expression was observed in the SMA-rich normal medium, with both proteins deposited at the cell periphery and/or the extracellular matrix ( Figure 6A ). In the calcified media with moderate calcification observed ( Figure 6A , von Kossa staining), IGF1R expression was increased ( Figure 6A ). OPG staining was nearly always stronger in calcified areas of the medium ( Figure 6A ). In contrast, high levels of calcification in plaque, displayed reduced IGF1R staining ( Figure 6A ). These findings demonstrate that IGF1R and OPG expression can be identified in atherosclerotic tissue, and that these proteins are differentially deposited in the vessel wall, dependent on the level of calcification observed.
Discussion
A significant predictor for cardiovascular events, vascular calcification, is present in patients with atherosclerosis, diabetic vasculopathy, chronic kidney disease, and aging. Vascular calcification is a complex process associated with expression of proteins initiating or inhibiting mineralization in the vessel wall. 2, 26 VSMCs play an important role in calcification as they can undergo phenotypic transformation to osteoblastlike cells. 26 In vitro, VSMCs can experience vesicle-mediated calcification in response to calcium, 19 and, in vivo, elevated serum calcium may act as a predictor of cardiovascular events in men. 27 The consistent synchrony observed for calcification of vessels and bone loss described in clinical studies 28 can be recapitulated in animal models with targeted deletion of a single gene demonstrating a combined phenotype of vascular calcification and osteoporosis. OPG 2/2 mice exhibit such a vascular and bone phenotype, with severe osteoporosis and calcification of the aorta and renal arteries. 4 OPG has been shown to inhibit osteoclasts by blocking the receptor activator of NFkB ligand (RANKL), the principal regulator of osteoclastic maturation and function. 29 Although animal models suggest a protective role for OPG against vascular calcification,
the mechanism of action is unknown and these findings have not been replicated in human trials. In fact, clinical studies show increased circulating OPG in patients with vascular disease, which may support a causative role for OPG in calcification processes. 30, 31 Thus, the precise role of OPG in the vascular system is still elusive. Recently, IGF1 signalling was implicated in the regulation, proliferation, and osteoblastic differentiation of calcifying vascular cells. 15 Here, we have defined a novel role for IGF1R in calcification of VSMCs in vitro. While moderate levels of exogenous calcium could stimulate calcification in kinase-inactive IGF1R-expressing cells, no calcification was observed in VSMCs expressing the wild-type, suggesting that IGF1R expression and activity can inhibit calcium-induced calcification. Furthermore, we identified that calcium and OPG could modulate IGF1R expression, a finding that was blocked by OPG gene silencing. Moderate levels of exogenous calcium induced OPG expression in VSMCs, a finding also observed in osteoblasts. 22 Interestingly, OPG-inducible IGF1R expression was biphasic: low (physiological) OPG concentrations were able to up-regulate IGF1R, while high (pathological) OPG, mimicking the high circulating OPG levels commonly detected in patients with vascular disease 31 and also in atherosclerotic plaques at sites of cell death, 32 could not induce expression of IGF1R ( Figure 6B ). Thus, although calcium induction of OPG and IGF1R may be protective, this effect could be overwhelmed with time, when continuous stimulation results in high OPG concentrations, which, as shown here, is unable to induce IGF1R ( Figure 3D) IGF1R inhibits VSMC calcification via OPG in serum OPG. 34 Other disorders are also associated with increased circulating OPG concentrations, such as diabetes mellitus and aging. 35, 36 These are all high-risk conditions to develop vascular calcification. Of note, observational studies in patients with atherosclerosis of different vascular beds found uniformly increased OPG levels in association with vascular calcification, coronary artery disease, stroke, and future cardiovascular events. 30, 31 This has led to a debate on OPG's role as a biomarker of vascular disease rather than a mediator of vascular pathology. The RANKL/OPG ratio is critical in bone remodelling and bone mass, and imbalances in this ratio or in RANK signalling can lead to bone pathologies. RANKL expression has been detected in calcified arterial tissue 37 and in recent studies using animal models, increased vascular calcium content has been associated with increased RANKL expression, both localized to calcified areas. 38 Interestingly in this study, the blood level ratio of RANKL/OPG remained unchanged. 38 This may indicate a parallel increase of OPG and RANKL, with the double-negative effect that increased RANKL induces VSMC calcification, whereas increased OPG fails to up-regulate protective IGF1R. Whether RANKL can influence IGF1R levels remains to be determined. The data presented here may have clinical implications for osteoporosis therapy. Denosumab, a monoclonal antibody against RANKL, offers a novel concept to treat low bone mass. Given the hypothesis that treatment of osteoporosis may also ameliorate vascular calcification, this antibody may have the potential to decrease vascular calcification. In fact, in glucocorticoid-treated human RANKL knock-in (hRANKL KI) mice, a preclinical model to test the pharmacological effects of denosumab-treated mice had less vascular calcium load compared with control mice. 39 Given the biphasic effect of OPG with vasculoprotection only at lower concentrations, anti-resorptive denosumab therapy in osteoporosis may prove superior to OPG therapy, since denosumab treatment does not change OPG serum concentrations. Administration of exogenous OPG in osteoporosis therapy regimens may have the detrimental effect of high circulating OPG, which may impinge on IGF1R expression. IGF1R is an anti-apoptotic factor, and increased apoptosis has been reported to act as a nidus for calcification. 40 Calcium phosphate crystals could destabilize atherosclerotic plaques by initiating inflammation and causing VSMC death, therefore anti-apoptotic effects may be important in maintaining vessel wall integrity. In fact, reduced IGF1 levels correlate with increased sensitivity to apoptosis, 41 and reduced IGF1R expression in human plaque VSMC 10 may be an important determinant of cell fate in the plaque. In this study, we found that calcium dose-dependently and significantly inhibited CAM-induced apoptosis. Calcium treatment increased expression of the anti-apoptotic protein Bcl2, and also NFkB, a transcription factor involved in the regulation of many survival genes including IGF1R. 42 OPG alone can exert anti-apoptotic effects in tumour cells. 43 It is tempting to speculate that the anti-apoptotic effects in other cell types may also be mediated by OPG-induced IGF1R up-regulation. Sp1, an ubiquitous transcription factor known to bind GGGCGG or related GC-rich sequences, has been implicated in regulation of bone matrix proteins. 44, 45 In this study, we found that OPG regulates IGF1R expression, and this effect was Sp1-dependent since overexpression of DN-Sp1 was able to block OPG-and calcium-inducible IGF1R expression. Of note, polymorphisms in COL1A1 gene have been found to alter bone strength by altering binding affinity for Sp1. 46 In summary, our findings suggest a feedback mechanism involving calcium signalling and regulation of IGF1R expression via OPG ( Figure 6B ). Here, we show for the first time direct evidence that IGF1R activity and expression can modulate VSMC calcification in vitro. Moderate levels of exogenous calcium (3.1 -3.3 mM) can increase OPG, which subsequently increase IGF1R, one of the most potent anti-apoptotic growth factors for VSMCs. This in turn leads to inhibition of calcification in vitro and may explain the vascular phenotype observed in OPG-deficient mice.
